Bone marrow mesenchymal stem cell–derived exosomes effectively ameliorate the outcomes of rats with acute graft‐versus‐host disease

Abstract Mesenchymal stem cells (MSCs) reveal multifaceted immunoregulatory properties, which can be applied for diverse refractory and recurrent disease treatment including acute graft‐versus‐host disease (aGVHD). Distinguishing from MSCs with considerable challenges before clinical application, MSCs‐derived exosomes (MSC‐Exos) are cell‐free microvesicles with therapeutic ingredients and serve as advantageous alternatives for ameliorating the outcomes of aGVHD. MSC‐Exos were enriched and identified by western blotting analysis, NanoSight, and transmission electron microscopy (TEM). Bone marrow–derived MSCs (denoted as MSCs) and exosomes (denoted as MSC‐Exos) were infused into the aGVHD SD‐Wister rat model via tail vein, and variations in general growth and survival of rats were observed. The level of inflammatory factors in serum was quantized by enzyme‐linked immunosorbent assay (ELISA). The pathological conditions of the liver and intestine of rats were observed by frozen sectioning. The ratios of CD4 + /CD8 + and T reg cell proportions in peripheral blood, together with the autophagy in the spleen and thymus, were analyzed by flow cytometry. After treatment with MSC‐Exos, the survival time of aGVHD rats was prolonged, the clinical manifestations of aGVHD in rats were improved, whereas the pathological damage of aGVHD in the liver and intestine was reduced. According to ELISA, we found that MSC‐Exos revealed ameliorative effect upon aGVHD inflammation (e.g., TNF‐α, IL‐2, INF‐γ, IL‐4, and TGF‐β) compared to the MSC group. After MSC‐Exo treatment, the ratio of T reg cells in peripheral blood was increased, whereas the ratio of CD4 + /CD8 + in peripheral blood and the autophagy in the spleen and thymus was decreased. MSC‐Exos effectively suppressed the activation of immune cells and the manifestation of the inflammatory response in the aGVHD rat model. Our data would supply new references for MSC‐Exo‐based “cell‐free” biotherapy for aGVHD in future.